Despite facing headwinds, Abbott Laboratories (ABT) reports robust earnings growth and outlines plans for innovation and ...

The medical-products maker’s shares tumbled after its quarterly profit and sales underwhelmed investors.

FILE PHOTO: Abbott Laboratories logo is displayed on a screen at the NYSE in New York (Reuters) -Abbott Laboratories will stop sales of its Similac Probiotic Tri-Blend product used for hospitalized ...

ADJUSTED EARNINGS: Stripping out certain one-time items, earnings are forecast to come in at $1.50 a share. That compares with adjusted earnings of $1.34 a share a year earlier. REVENUE: Quarterly ...

Abbott Laboratories forecast a 1Q profit that was lower than Wall Street expected and missed 4Q sales estimates after its ...

Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. Abbott Laboratories has agreed to discontinue sales of its ...

A California federal judge has reportedly allowed litigation to proceed against Abbott Laboratories (NYSE:ABT) regarding its Glucerna shakes and nutritional powders. The lawsuit claims these products, ...

Santa Ana-based Abbott Medical Optics Inc. is readying a product push. The maker of eye surgery devices, part of Chicago-area drug and medical device maker Abbott Laboratories, has plans for 20 new ...

Abbott Laboratories reported a 4% increase in quarterly sales, totalling $10.4 billion. The company released its latest earnings report Thursday and subsequently revised its full-year financial ...